Drug Trial Radar · NCT05201248
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Actual
Start
Mar 10, 2022
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Jan 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and toxicity of epcoritamab as a monotherapy and when combined with standard of care therapy \[Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or Rituximab and lenalidomide (R2)\] in adult participants in China with B-Cell Non-Hodgkin Lymphoma. Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of B-Cell Non-Hodgkin Lymphoma. Study doctors put the participants in groups called treatment arms. A monotherapy of epcoritamab and two different combination of epcoritamab with standard of care therapy (R-CHOP or R2) will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. Approximately 66 adult participants with B-Cell Non-Hodgkin Lymphoma will be enrolled in the study in approximately 21 sites in China. In the monotherapy arm (Cohort 1), participants will receive subcutaneous epcoritamab in 28-day cycles. In the combination arms (Cohorts 2 and 3), participants in Cohort 2 will receive subcutaneous epcoritamab with standard of care therapy (R-CHOP) in 21-day cycles followed by 28-day cycles, participants in Cohort 3 will receive subcutaneous epcoritamab with standard of care therapy (R2) in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- B-Cell Non-Hodgkin Lymphoma
Interventions
EpcoritamabDrug
Subcutaneous Injection (SC)
CyclophosphamideDrug
IV Injection
RituximabDrug
Intravenous (IV) Infusion
DoxorubicinDrug
IV Infusion
VincristineDrug
IV Infusion
PrednisoneDrug
Oral; Tablet
LenalidomideDrug
Oral; Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1 Part 2 [(3L+) R/R DLBCL]: Best Overall Response (BOR)Time frame: Up to Approximately 5 Years
- Cohort 1 Part 1, Cohort 2, and Cohort 3: Number of Incidence of Dose-Limiting Toxicities (DLT)Time frame: Up to Approximately 5 Years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
The Fifth Medical Center of PLA General Hospital /ID# 230520
Beijing, Beijing Municipality, China
Peking University Third Hospital /ID# 228138
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital /ID# 231890
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center /ID# 228033
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital /ID# 228028
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University /ID# 227916
Guangzhou, Guangdong, China
Henan Cancer Hospital /ID# 228772
Zhengzhou, Henan, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221
Wuhan, Hubei, China
Hunan Cancer Hospital /ID# 231859
Changsha, Hunan, China
The First Affiliated Hospital of Soochow University /ID# 228024
Suzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical College /ID# 228774
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University /ID# 228771
Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital /ID# 231944
Nanchang, Jiangxi, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University /ID# 231434
Chengdu, Sichuan, China
Tianjin Cancer Hospital /ID# 228135
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 228154
Hangzhou, Zhejiang, China
Zhejiang Cancer hospital /ID# 228776
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.